EA201491694A1 - Лечение рака ингибиторами tor киназы - Google Patents

Лечение рака ингибиторами tor киназы

Info

Publication number
EA201491694A1
EA201491694A1 EA201491694A EA201491694A EA201491694A1 EA 201491694 A1 EA201491694 A1 EA 201491694A1 EA 201491694 A EA201491694 A EA 201491694A EA 201491694 A EA201491694 A EA 201491694A EA 201491694 A1 EA201491694 A1 EA 201491694A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tor kinase
kinase inhibitors
cancer treatment
ets
overexpression
Prior art date
Application number
EA201491694A
Other languages
English (en)
Other versions
EA028434B1 (ru
Inventor
Шуйчань Сюй
Кристен Мей Хедж
Original Assignee
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA201491694A1 publication Critical patent/EA201491694A1/ru
Publication of EA028434B1 publication Critical patent/EA028434B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Представлены способы лечения или профилактики саркомы Юинга со сверхэкспрессией ETS, включающие введение эффективного количества ингибитора TOR киназы пациенту, страдающему саркомой Юинга со сверхэкспрессией ETS.
EA201491694A 2012-03-15 2013-03-14 Лечение рака ингибиторами tor киназы EA028434B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611370P 2012-03-15 2012-03-15
US201261715329P 2012-10-18 2012-10-18
PCT/US2013/031202 WO2013138556A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201491694A1 true EA201491694A1 (ru) 2015-06-30
EA028434B1 EA028434B1 (ru) 2017-11-30

Family

ID=47998542

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491694A EA028434B1 (ru) 2012-03-15 2013-03-14 Лечение рака ингибиторами tor киназы

Country Status (21)

Country Link
US (1) US20130245029A1 (ru)
EP (1) EP2825168B1 (ru)
JP (2) JP2015516375A (ru)
KR (3) KR20200034818A (ru)
CN (2) CN104302295B (ru)
AU (1) AU2013203156C1 (ru)
BR (1) BR112014022697A2 (ru)
CA (1) CA2867349A1 (ru)
EA (1) EA028434B1 (ru)
ES (1) ES2677908T3 (ru)
HK (1) HK1201755A1 (ru)
IL (2) IL234640B (ru)
MX (1) MX360877B (ru)
MY (1) MY182650A (ru)
NI (1) NI201400109A (ru)
NZ (1) NZ628421A (ru)
PH (2) PH12014502048B1 (ru)
SG (1) SG11201405706TA (ru)
TW (2) TWI664968B (ru)
WO (1) WO2013138556A1 (ru)
ZA (1) ZA201406709B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2897985A1 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105339008A (zh) 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
ES2744198T3 (es) 2013-04-17 2020-02-24 Signal Pharm Llc Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TWI656875B (zh) 2013-04-17 2019-04-21 美商標誌製藥公司 藉二氫吡并吡治療癌症
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
CA2955009A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
UA123032C2 (uk) 2016-12-20 2021-02-03 Астразенека Аб Амінотриазолопіридинові сполуки та їхнє застосування у лікуванні раку
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
CN113960808A (zh) * 2018-03-01 2022-01-21 依视路国际公司 镜片元件
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679432B (zh) * 2006-10-19 2015-04-22 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
KR20140104060A (ko) * 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
RU2557242C2 (ru) 2009-10-26 2015-07-20 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы получения и очистки гетероарильных соединений
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
IL234640A0 (en) 2014-11-30
KR20140138929A (ko) 2014-12-04
JP2015516375A (ja) 2015-06-11
TWI600428B (zh) 2017-10-01
PH12018502234B1 (en) 2019-08-14
MY182650A (en) 2021-01-27
KR102057358B1 (ko) 2019-12-18
NZ628421A (en) 2016-04-29
BR112014022697A2 (pt) 2020-06-30
KR20190058673A (ko) 2019-05-29
EP2825168B1 (en) 2018-05-09
TWI664968B (zh) 2019-07-11
AU2013203156B2 (en) 2015-12-10
MX360877B (es) 2018-11-21
NI201400109A (es) 2015-01-15
PH12018502234A1 (en) 2019-08-14
US20130245029A1 (en) 2013-09-19
MX2014011117A (es) 2015-04-08
PH12014502048A1 (en) 2014-12-10
KR20200034818A (ko) 2020-03-31
CA2867349A1 (en) 2013-09-19
AU2013203156A1 (en) 2013-10-03
SG11201405706TA (en) 2014-10-30
TW201343167A (zh) 2013-11-01
JP2018065820A (ja) 2018-04-26
CN104302295B (zh) 2017-06-20
HK1201755A1 (en) 2015-09-11
TW201733586A (zh) 2017-10-01
PH12014502048B1 (en) 2014-12-10
EP2825168A1 (en) 2015-01-21
CN107137402A (zh) 2017-09-08
AU2013203156C1 (en) 2016-02-18
JP6470821B2 (ja) 2019-02-13
EA028434B1 (ru) 2017-11-30
ZA201406709B (en) 2016-07-27
CN104302295A (zh) 2015-01-21
IL274318A (en) 2020-06-30
WO2013138556A1 (en) 2013-09-19
ES2677908T3 (es) 2018-08-07
IL234640B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
EA201890768A3 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
EA201591509A1 (ru) Ингибиторы cdc7
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
GEP20186900B (en) Methods of treating cancer using aurora kinase inhibitors
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU